- Oral presentation
- Open Access
Lateral wedge shoe insoles for medial knee osteoarthritis: a 12-month randomised controlled trial
© Bennell et al; licensee BioMed Central Ltd. 2011
- Published: 20 May 2011
- Numeric Rating Scale
- Cartilage Defect
- Structural Outcome
- Bone Marrow Lesion
- Medial Knee
The majority of clinical guidelines recommend lateral wedge shoe insoles for medial knee osteoarthritis (OA), despite limited and equivocal evidence of efficacy. The objective of this study was to assess efficacy of lateral wedge insoles for improving symptoms and slowing structural disease progression compared with control insoles in medial knee OA.
A randomised participant- and assessor-blinded controlled trial was used. 200 people aged 50 or more with clinical and radiographic diagnosis of mild-to-moderately severe medial knee OA were recruited. The interventions consisted of full-length 5° lateral wedged insoles or flat control insoles worn inside the shoes daily for 12 months. The primary symptomatic outcome was change in overall knee pain (past week) measured on an 11-point numeric rating scale and primary structural outcome was change in medial tibial cartilage volume from magnetic resonance imaging. Secondary clinical outcomes included changes in measures of pain, function, stiffness, and health-related quality of life. Secondary structural outcomes included progression of medial cartilage defects and bone marrow lesions.
There were no significant between-group differences for the primary outcomes of change in overall pain (-0.3 points 95% CI (-1.0 to 0.3)) and change in medial tibial cartilage volume (-0.4 mm3 (-15.4 to 14.6)). None of the changes in secondary outcomes demonstrated differences between groups.
In this study, lateral wedge insoles worn for 12 months provided no symptomatic or structural benefits compared to a flat control insole.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.